Davion lists on Nasdaq at a $306M reference price, then falls 90%
What's the deal? Davion HealthCareDealroom has a profile for this one. Try Dealroom →, a British company, made its Nasdaq debut on October 22, 2026, through a direct listing of 25 million existing shares under the ticker DAVI. The listing carried a $12 reference price — implying a roughly $306 million value — but shares have since collapsed to about $1, a drop of more than 90%.
The important caveat: this was not a $306 million fundraising. A direct listing raises no new capital, and the $12 reference price was not an offer price investors paid. The headline figure reflects the value of existing shares, not money that flowed into the company.
Why now? The US IPO market was subdued in October, though healthcare deals did get done. The listing coincided with a change in Davion's senior leadership.
What's the endgame? Davion's prospectus described products still to be commercialised, including a non-diagnostic breast self-check. Since listing, it has announced a $25 million purchase of medical-technology IP and a proposed $13.5 million home-care acquisition, with much of the first deal's consideration in shares valued contractually at $13.
What could go wrong? With a thinly evidenced commercial story and ambitious acquisition plans, execution, funding, and the basis for those contractual valuations are open questions. In early November, Davion appointed Vienna Capital PartnersDealroom has a profile for this one. Try Dealroom → to support a financing strategy for acquisitions it has put at more than $100 million for 2027.
The signal: Davion's plunge is less a sector-wide IPO rout — peers like Lycia Therapeutics have traded sharply higher since listing — than a warning about how debuts are read. A direct-listing reference price is not money raised, nor proof of value, and investors should treat the two very differently.
Read more: shareprophets.com
Image credit: agilemktg1
